-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Clinical Discussant for Transplant

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium I: Targeted, Gene and Cellular Therapy - Recent Approvals in Non-Malignant Hematology
Monday, December 11, 2023, 10:30 AM-12:00 PM

Navneet Majhail, MD, MS, FASTCT

Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN

Disclosures: Majhail: Anthem Inc: Membership on an entity's Board of Directors or advisory committees.